June 1, 2020 / 11:27 AM / a month ago

BRIEF-Compugen Reports FDA Clearance Of IND Application For Phase 1/2 Triple Combination Study Of COM701

June 1 (Reuters) - Compugen Ltd:

* COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR PHASE 1/2 TRIPLE COMBINATION STUDY OF COM701 WITH BRISTOL MYERS SQUIBB’S OPDIVO® (NIVOLUMAB) AND TIGIT INHIBITOR

* COMPUGEN - ON-TRACK TO BEGIN TRIPLE COMBINATION STUDY DURING SECOND HALF OF 2020

* COMPUGEN - COM701 TRIPLE COMBINATION STUDY TO EVALUATE SIMULTANEOUS BLOCKADE OF PVRIG, TIGIT & PD-1 IMMUNE CHECKPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below